BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Relacorilant (Lifyorli) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Relacorilant (Lifyorli)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03604198-399@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT03604198)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2\, Cushing's Syndrome.\nStudy:
  Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant i
 n Patients With Cushing Syndrome\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/relacorilant-lif
 yorli#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03604198
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259317-399@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT07259317)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2.\nStudy: Relacorilant With Na
 b-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenoc
 arcinoma\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07259317
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05726292-399@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT05726292)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2.\nStudy: A Study of Enzalutam
 ide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placeb
 o for Patients With High-risk Localized Prostate Cancer\nEstimated primary
  completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/relacorilant-lifyorli#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05726292
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906341-399@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT06906341)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2\, Ovarian Cancer.\nStudy: Rel
 acorilant in Combination With Different Treatment Regimens in Patients Wit
 h Gynecological Cancers\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/relacorilant-lifyorli#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0690634
 1
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925801-399@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Relacorilant (Lifyorli): Phase 1/2 readout est. (NCT07925801)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 1/2.\nStudy: Relacorilant in Pa
 tients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secr
 etion\nEstimated primary completion: 15 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07925801
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07763496-399@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT07763496)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2.\nStudy: Relacorilant and Nab
 -Paclitaxel in Recurrent or Metastatic Cervical Cancer\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/relacorilant-lifyorli#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07763496
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
